Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial

Yogish C. Kudva, Lori M. Laffel, Sue A. Brown, Dan Raghinaru, Jordan E. Pinsker, Laya Ekhlaspour, Carol J. Levy, Laurel H. Messer, Boris P. Kovatchev, John W. Lum, Roy W. Beck, Linda Gonder-Frederick

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC (N = 112) versus SAP (N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.

Original languageEnglish
Pages (from-to)673-683
Number of pages11
JournalDiabetes Technology and Therapeutics
Volume23
Issue number10
DOIs
StatePublished - 1 Oct 2021

Keywords

  • Adolescents
  • Adults
  • Diabetes distress
  • Hypoglycemia awareness
  • Hypoglycemia fear
  • Patient-reported outcomes
  • Usability

Fingerprint

Dive into the research topics of 'Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial'. Together they form a unique fingerprint.

Cite this